Entellus Medical Inc (NASDAQ:ENTL) has been given a $18.00 target price by analysts at Canaccord Genuity in a report issued on Monday. The brokerage currently has a “hold” rating on the medical technology company’s stock. Canaccord Genuity’s price target would suggest a potential upside of 34.73% from the company’s current price.
Several other equities analysts have also recently issued reports on ENTL. Zacks Investment Research cut Entellus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, January 31st. BTIG Research cut Entellus Medical from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 22nd. Bank of America Corp cut Entellus Medical from a “buy” rating to an “underperform” rating and set a $16.00 target price on the stock. in a research note on Wednesday, February 22nd. Finally, William Blair reiterated an “outperform” rating on shares of Entellus Medical in a research note on Wednesday, May 10th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $21.83.
Entellus Medical (NASDAQ:ENTL) opened at 13.36 on Monday. Entellus Medical has a 52 week low of $11.47 and a 52 week high of $22.63. The firm has a 50-day moving average of $13.68 and a 200 day moving average of $16.08. The firm’s market capitalization is $292.80 million.
Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings data on Wednesday, May 3rd. The medical technology company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.04. Entellus Medical had a negative return on equity of 53.20% and a negative net margin of 36.91%. The firm had revenue of $19.11 million for the quarter, compared to analysts’ expectations of $19.61 million. During the same period last year, the business posted ($0.37) earnings per share. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. Analysts predict that Entellus Medical will post ($1.36) earnings per share for the current year.
WARNING: “Entellus Medical Inc (ENTL) Given a $18.00 Price Target by Canaccord Genuity Analysts” was published by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://sleekmoney.com/entellus-medical-inc-entl-given-a-18-00-price-target-by-canaccord-genuity-analysts/1848197.html.
In related news, CFO Brent Moen bought 6,100 shares of the business’s stock in a transaction on Monday, May 8th. The shares were bought at an average cost of $12.21 per share, for a total transaction of $74,481.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert S. White bought 10,000 shares of the business’s stock in a transaction on Monday, May 8th. The stock was bought at an average price of $12.24 per share, for a total transaction of $122,400.00. The disclosure for this purchase can be found here. Insiders acquired 17,700 shares of company stock worth $216,625 over the last quarter. 9.10% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in Entellus Medical by 53.8% in the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock worth $102,000 after buying an additional 2,594 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in Entellus Medical by 5.6% in the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock worth $150,000 after buying an additional 573 shares during the last quarter. Teachers Advisors LLC boosted its stake in Entellus Medical by 17.4% in the first quarter. Teachers Advisors LLC now owns 12,369 shares of the medical technology company’s stock worth $171,000 after buying an additional 1,836 shares during the last quarter. Quinn Opportunity Partners LLC bought a new stake in Entellus Medical during the fourth quarter worth about $241,000. Finally, Swiss National Bank boosted its stake in Entellus Medical by 98.9% in the first quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock worth $244,000 after buying an additional 8,800 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/entellus-medical-inc-entl-given-a-18-00-price-target-by-canaccord-genuity-analysts/1848197.html
Receive News & Ratings for Entellus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.